SCHEMBL2377873

SCHEMBL2377873

CC1(C)OB(c2ccccc2CN(C(=O)O)c2ccccc2)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.37
ALDH1A1 P00352 3/20 0.37
GLA P06280 2/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
PAX8 Q06710 1/20 0.36
LPL P06858 1/20 0.36
LIPG Q9Y5X9 1/20 0.36
P4HB P07237 1/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
LTB4R2 Q9NPC1 3/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL774040 0.85 USP30 (0.38) CXCR2ALDH1A1GLATSHRTP53
SCHEMBL23536625 0.83 CXCR2 (0.39) CXCR2ALDH1A1NPC1RAB9ALPL
SCHEMBL773437 0.78 MEN1 (0.35) ALDH1A1GLATSHRTP53SMN1; SMN2
SCHEMBL4158920 0.77 AKR1B1 (0.46) CXCR2LPLLIPGP4HB
SCHEMBL23526249 0.76 LPL (0.40) CXCR2ALDH1A1TSHRSMN1; SMN2LPL
SCHEMBL534958 0.75 NPSR1 (0.39) CXCR2LPLLIPGMEN1KMT2A
SCHEMBL902458 0.74 LIPG (0.49) CXCR2ALDH1A1HTTLPLLIPG
SCHEMBL13202078 0.74 LPL (0.43) CXCR2LPLLIPGP4HB
SCHEMBL3078824 0.74 TSHR (0.39) CXCR2ALDH1A1TSHRHTTLPL
SCHEMBL19817457 0.73 CXCR2 (0.41) CXCR2ALDH1A1TSHRSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674040-B2 Pyridyldiamido transition metal complexes, production and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2014-03-18 US disclosed
EP-2688897-A1 PYRIDYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF Exxon-Mobil Chemical Patents Inc. (US) 2014-01-29 EP disclosed
WO-2012134614-A1 PYRIDYLDIAMIDO TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-10-04 WO disclosed
US-20110224391-A1 Pyridyldiamido Transition Metal Complexes, Production and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224391-A1 Pyridyldiamido Transition Metal Complexes, Production and Use Thereof PICALM, PARN, PCBP1 CXCR2 3914/4885ALDH1A1 2590/4885GLA 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.